Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer''s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest shares articles
GBP/USD attempts recovery as UK CPI rises once again
UK inflation rose unexpectedly in June, moving further away from the Bank of England's 2% and limiting the amount of future rate cuts
08:25, 16 July 2025
EUR/USD: bullish narrative tested by U.S. trade threats
US tariff threats weigh on euro sentiment as the dollar regains the upper hand
07:47, 15 July 2025
US CPI Preview: Inflation data to test Fed’s tariff assumptions and policy expectations
US CPI data could impact the Fed's views on tariffs, inflation and monetary policy
18:52, 14 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:59, 14 July 2025
Ratings and Reviews
Ratings and Reviews
